UOC
SLN

UBS O'Connor’s Silence Therapeutics SLN Stock Holding History

UBS O'Connor’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,639
Closed -$177K – 448
2025
Q1 		$177K Sell
62,639
-66,351
-51% -$324K ﹤0.01% 252
2024
Q4 		$887K Buy
128,990
+43,289
+51% +$559K 0.02% 241
2024
Q3 		$1.56M Buy
85,701
+8,861
+12% +$165K 0.04% 213
2024
Q2 		$1.46M Buy
76,840
+4,617
+6% +$98.2K 0.04% 238
2024
Q1 		$1.56M Sell
72,223
-20,975
-23% -$456K 0.04% 225
2023
Q4 		$1.62M Sell
93,198
-5,128
-5% -$57.6K 0.05% 208
2023
Q3 		$967K Hold
98,326
– – 0.02% 335
2023
Q2 		$541K Buy
98,326
+2,943
+3% +$17.7K 0.01% 440
2023
Q1 		$591K Buy
95,383
+6,447
+7% +$76K 0.01% 452
2022
Q4 		$1.36M Buy
88,936
+9,300
+12% +$122K 0.03% 531
2022
Q3 		$786K Buy
79,636
+50,820
+176% +$535K 0.01% 767
2022
Q2 		$341K Buy
+28,816
New +$350K ﹤0.01% 830

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

UBS O'Connor's SLN Position: Q2 2025 in Review

UBS O'Connor sold out of Silence Therapeutics (SLN) in Q2 2025, closing a stake of 62,639 shares — an estimated $177K sold.

UBS O'Connor first reported a position in SLN in Q2 2022 and held it in 12 quarters. The position peaked at $1.62M in Q4 2023. 55 funds tracked by Wall St. Rank hold SLN as of Q2 2025.

  • UBS O'Connor reported no remaining Silence Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 62,639 Silence Therapeutics shares in Q2 2025, an estimated $177K.
  • UBS O'Connor first reported a position in Silence Therapeutics in Q2 2022 and held it in 12 quarters.
  • UBS O'Connor's Silence Therapeutics position peaked at $1.62M in Q4 2023.
  • 55 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.